Abstract |
Approximately 0.5-1% of all newborns are born infected with cytomegalovirus (CMV), but of these only one out of ten show symptoms at birth, most often with hepatosplenomegaly, thrombocytopenia, and/or brain affection. Of the remaining nine, one may later develop sequelae with hearing loss and/or mental retardation. CMV infection may also be acquired perinatally or in the newborn period, and may cause pneumonia and/or sepsis, possibly also gastrointestinal symptoms like blood in the stool, and poor weight-gain. We have diagnosed CMV infection in ten neonates and infants, and describe these patients in terms of symptoms, diagnosis and treatment. Ganciclovir is being tested in clinical trials as a treatment for congenital CMV infection, and was given to two of our patients with apparently good results.
|
Authors | R B Fjaer, T G Abrahamsen, A L Bruu, T W Hansen |
Journal | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
(Tidsskr Nor Laegeforen)
Vol. 117
Issue 10
Pg. 1460-4
(Apr 20 1997)
ISSN: 0029-2001 [Print] Norway |
Vernacular Title | Cytomegalovirusinfeksjon hos nyfødte. Erfaringer med diagnostikk og behandling. |
PMID | 9198923
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Antiviral Agents
- Ganciclovir
|
Topics |
- Antiviral Agents
(therapeutic use)
- Cytomegalovirus Infections
(diagnosis, drug therapy)
- Female
- Ganciclovir
(therapeutic use)
- Gastrointestinal Diseases
(diagnosis, drug therapy)
- Humans
- Infant, Newborn
|